Home
/
Editas Medicine, Inc.
/
Financials
/
Quarterly
Editas Medicine, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Editas Medicine, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2019
Mar 31, 2019
$2.07M
May 8, 2019
Q3
2018
Sep 30, 2018
$14.52M
Nov 8, 2018
Q2
2018
Jun 30, 2018
$7.37M
Aug 7, 2018
Q1
2019
Mar 31, 2018
$3.93M
May 8, 2019
Q3
2018
Sep 30, 2017
$6.28M
Nov 8, 2018
Q2
2018
Jun 30, 2017
$3.10M
Aug 7, 2018
Q1
2018
Mar 31, 2017
$682.0K
May 4, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$7.54M
Nov 10, 2025
Q2
2025
Jun 30, 2025
$3.58M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$4.66M
May 12, 2025
Q3
2025
Sep 30, 2024
$61.0K
Nov 10, 2025
Q2
2025
Jun 30, 2024
$513.0K
Aug 12, 2025
Q1
2025
Mar 31, 2024
$1.14M
May 12, 2025
Q3
2024
Sep 30, 2023
$5.34M
Nov 4, 2024
Q2
2024
Jun 30, 2023
$2.89M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$9.85M
May 8, 2024
Q3
2023
Sep 30, 2022
$42.0K
Nov 3, 2023
Q2
2023
Jun 30, 2022
$6.36M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$6.77M
May 5, 2023
Q3
2022
Sep 30, 2021
$6.20M
Nov 2, 2022
Q2
2022
Jun 30, 2021
$379.0K
Aug 3, 2022
Q1
2022
Mar 31, 2021
$6.50M
May 4, 2022
Q3
2021
Sep 30, 2020
$62.84M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$10.75M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$5.72M
May 6, 2021
Q3
2020
Sep 30, 2019
$3.85M
Nov 6, 2020
Q2
2020
Jun 30, 2019
$2.33M
Aug 7, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($25.12M)
Nov 10, 2025
Q3
2025
Jun 30, 2025
($53.24M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($53.24M)
Aug 12, 2025
Q3
2025
Mar 31, 2025
($76.09M)
Nov 10, 2025
Q1
2025
Mar 31, 2025
($76.09M)
May 12, 2025
Q2
2025
Mar 31, 2025
($76.09M)
Aug 12, 2025
Q3
2025
Sep 30, 2024
($62.14M)
Nov 10, 2025
Q3
2025
Jun 30, 2024
($67.61M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($67.61M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($61.95M)
May 12, 2025
Q3
2025
Mar 31, 2024
($61.95M)
Nov 10, 2025
Q2
2025
Mar 31, 2024
($61.95M)
Aug 12, 2025
Q3
2024
Sep 30, 2023
($45.02M)
Nov 4, 2024
Q2
2024
Jun 30, 2023
($40.29M)
Aug 7, 2024
Q3
2024
Jun 30, 2023
($40.29M)
Nov 4, 2024
Q1
2024
Mar 31, 2023
($49.04M)
May 8, 2024
Q2
2024
Mar 31, 2023
($49.04M)
Aug 7, 2024
Q3
2024
Mar 31, 2023
($49.04M)
Nov 4, 2024
Q3
2023
Sep 30, 2022
($55.73M)
Nov 3, 2023
Q3
2023
Jun 30, 2022
($53.45M)
Nov 3, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($24.55M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($51.54M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($76.16M)
May 12, 2025
Q3
2025
Sep 30, 2024
($65.67M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($71.90M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($66.99M)
May 12, 2025
Q3
2024
Sep 30, 2023
($50.16M)
Nov 4, 2024
Q2
2024
Jun 30, 2023
($44.09M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($50.96M)
May 8, 2024
Q3
2023
Sep 30, 2022
($57.52M)
Nov 3, 2023
Q2
2023
Jun 30, 2022
($54.23M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($50.75M)
May 5, 2023
Q3
2022
Sep 30, 2021
($39.25M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($55.40M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($56.88M)
May 4, 2022
Q3
2021
Sep 30, 2020
$8.99M
Nov 9, 2021
Q2
2021
Jun 30, 2020
($31.34M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($46.62M)
May 6, 2021
Q3
2020
Sep 30, 2019
($34.59M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($35.65M)
Aug 7, 2020